Close Menu

stock price

The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.

It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.

A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.

The GenomeWeb Index fell half a percent in June, underperforming the Dow Jones Industrial Average, but far outpacing the Nasdaq and Nasdaq Biotech Index.

The GenomeWeb Index rose 4 percent in May, in line with the Nasdaq and the Nasdaq Biotech Index, and outperforming the Dow Jones Industrial Average.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.